rs17250932 — TBX21 TBX21 Promoter Variant

Upstream promoter variant in TBX21 that reduces neonatal IL-5 and IL-13 secretion after innate immune stimulation; the minor C allele dampens Th2 cytokine output at birth, suggesting a role in early-life immune programming and atopic susceptibility through reduced TBX21 transcriptional drive

See your personal result for TBX21

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TBX21 Promoter — Neonatal Th2 Cytokine Programming and Atopic Risk

The TBX21 gene encodes T-bet, the master transcription factor that drives naive CD4+ T cells toward the Th1 differentiation path11 Th1 differentiation path
Th1 cells produce IFN-γ and suppress IgE production; when T-bet is robust, Th2 overactivation — the driver of allergic disease — is held in check. rs17250932 is a single-nucleotide variant situated approximately 1.5 kilobases upstream of the TBX21 transcription start site in the promoter region. The position is designated -1514T/C in the literature (numbering from the start codon) — the T allele is the common reference, the C allele the minor variant. Unlike the well-characterized downstream promoter variant rs4794067 (-1993T/C), rs17250932 has not been studied in functional promoter activity assays, but its proximity to the transcription start site places it squarely in the regulatory region where transcription factor binding determines how strongly TBX21 is expressed.

The Mechanism

Variants in the TBX21 upstream promoter region influence binding of transcriptional activators and repressors to core promoter elements. The related -1993T/C variant (rs4794067)22 related -1993T/C variant (rs4794067)
Akahoshi et al. Hum Genet 2005; the C allele creates a novel nuclear protein binding site, directly increasing TBX21 transcriptional activity and associating with aspirin-induced asthma at OR 1.93 demonstrates that single-nucleotide changes in this promoter region have direct, measurable effects on TBX21 expression. For rs17250932, the functional readout is cytokine-level: in a German birth cohort of 200 neonates, Casaca et al. 201233 Casaca et al. 2012
TBX21 and HLX1 polymorphisms influence cytokine secretion at birth; PLoS One; cord blood mononuclear cells genotyped and stimulated with lipid A (LpA) found that carriers of the C allele showed reduced or trendwise-reduced (p ≤ 0.07) secretion of IL-5, IL-13, and TNF-α after innate immune stimulation with lipid A. IL-5 and IL-13 are canonical Th2 effector cytokines — IL-5 drives eosinophil maturation and survival, while IL-13 promotes mucus production, airway hyperresponsiveness, and IgE class-switching. Reduced secretion of these cytokines at birth suggests that C allele carriers are born with a less Th2-primed innate immune response, providing a window of relative protection during the critical early-life immune programming period.

The T allele (common, reference) is associated with higher neonatal Th2 cytokine output — a pro-atopic starting point that, when compounded by environmental triggers (antibiotic exposure, low microbial diversity, allergen sensitization), can translate into clinical atopic disease by the third year of life.

The Evidence

The primary atopic evidence comes from the Casaca et al. 2012 birth cohort44 Casaca et al. 2012 birth cohort
200 German neonates; cord blood mononuclear cells genotyped for TBX21 and HLX1 polymorphisms; cytokine secretion measured after LpA stimulation; children followed to age 3 for atopic disease outcomes. Among the 184 genotyped neonates, 113 were TT homozygotes, 61 were TC heterozygotes, and 10 were CC homozygotes. Carriers of the C allele (TC + CC combined) showed reduced IL-5 and IL-13 secretion after innate stimulation — the direction consistent with attenuated neonatal Th2 polarization. The statistical threshold was p ≤ 0.07, reflecting the limited statistical power of a 200-person cohort where only 71 carry at least one C allele. This must be counted as [emerging evidence | a p-value of 0.07 does not meet the conventional 0.05 threshold; the signal is directionally consistent with the TBX21 biology but requires replication in larger cohorts].

The broader TBX21 promoter context extends the picture. In a Japanese autoimmune study, the T allele of the related -1514T/C position55 T allele of the related -1514T/C position
Morita et al. Autoimmunity 2012; 66 intractable GD patients, 47 GD remission, 79 controls was enriched in patients with intractable Graves' disease compared to those who achieved remission — suggesting that the T allele promotes stronger TBX21-driven Th1 immune activity, which in the autoimmune context amplifies disease persistence. A Chinese SLE study66 Chinese SLE study
You et al. Scand J Rheumatol 2010; 248 SLE cases, 261 controls found the -1514T allele significantly more frequent in SLE patients, and that the CC haplotype (-1993C/-1514C) was protective against SLE with OR 0.316 (95% CI 0.167–0.599, p = 0.0004). A subsequent meta-analysis in Asian populations77 meta-analysis in Asian populations
Wang et al. Allergol Immunopathol 2021; 12 studies, 3,834 cases, 4,824 controls did not confirm rs17250932 as a significant autoimmune risk variant in pooled analysis, tempering the earlier single-study SLE signal. Taken together, the evidence is consistent with the C allele reducing TBX21 promoter output — less T-bet means less Th1 (and Th2) cytokine drive, an effect that is measurably protective for neonatal Th2-mediated atopy, and potentially modulates the Th1-driven autoimmune phenotype as well.

Practical Actions

TT homozygotes — the common form carried by roughly 70% of people globally — show the highest neonatal IL-5/IL-13 output at innate stimulation and represent the atopy-susceptible reference. For TT carriers who develop or whose infants develop atopic symptoms, the TBX21 genetic context supports interventions targeting the Th2 cytokine axis: specifically IL-5-driven eosinophilia and IL-13-driven airway and skin inflammation.

TC and CC carriers demonstrate attenuated neonatal Th2 cytokine production. The CC genotype is rare (~2.6% globally), and no prospective atopic outcome data for CC specifically are available from this small cohort (only 10 CC participants in Casaca 2012). The evidence does not support treating CC individuals as categorically protected from atopic disease.

Interactions

rs17250932 lies in the TBX21 5' regulatory region, approximately 500 bp upstream of the better-characterized rs4794067 (-1993T/C) promoter variant. These two promoter variants are in partial linkage disequilibrium — the protective CC haplotype spanning both positions (rs4794067-C/rs17250932-C) was the SLE-protective configuration in You et al. 2010. Within the TBX21 locus, the other variants rs11079788 (intron 3, Treg-related) and rs11650354 + rs16947078 (allergic asthma risk haplotype) are in separate LD blocks and likely operate through distinct regulatory mechanisms. HLX1 variants (including rs2738751) interact with TBX21 polymorphisms to amplify their effects on both neonatal cytokine output and childhood asthma risk.

Genotype Interpretations

What each possible genotype means for this variant.

CT Intermediate Th2 Cytokine Output Normal

One C allele associated with intermediate neonatal IL-5 and IL-13 levels

You carry one copy of the common T allele and one copy of the minor C allele at rs17250932. Approximately 27% of people globally carry this heterozygous genotype. In the Casaca 2012 birth cohort, TC heterozygotes showed intermediate or reduced IL-5 and IL-13 secretion after innate immune stimulation compared to TT homozygotes. The protective effect of the C allele on neonatal Th2 cytokine output appears to operate in an additive fashion — one copy provides partial dampening of the IL-5/IL-13 response. The evidence for rs17250932 itself is preliminary (a single birth cohort study of 200 neonates), and the overall risk difference between genotypes at this specific variant is modest.

CC Reduced Neonatal Th2 Cytokine Output Beneficial

Homozygous minor allele form associated with the lowest neonatal IL-5 and IL-13 secretion

The CC genotype at this TBX21 upstream promoter position carries two copies of the minor C allele, which is associated with reduced neonatal Th2 cytokine secretion (IL-5, IL-13) in response to innate immune stimulation with lipid A. This suggests lower TBX21 promoter-driven immune activity producing fewer Th2-promoting cytokines at birth. An interesting counter-context: in Chinese autoimmune cohorts, the -1514C allele (rs17250932-C) combined with the -1993C allele (rs4794067-C) defines the haplotype protective against systemic lupus erythematosus (CC haplotype OR 0.316, p = 0.0004), and the T allele is enriched in intractable Graves' disease. This pattern is consistent across these immune contexts: the C allele broadly reduces TBX21 promoter-driven cytokine output — a feature that is protective against Th2 atopic disease and against Th1-driven autoimmune disease. The small cohort size (10 CC individuals in Casaca 2012) means this evidence remains at the emerging level.

TT Common TBX21 Promoter Form Intermediate

Common homozygous form with highest neonatal Th2 cytokine output after innate stimulation

The TT genotype represents the population baseline at this TBX21 upstream promoter position. The cytokine findings from Casaca 2012 show that TT neonates generate higher innate-stimulated IL-5 and IL-13 than C allele carriers at birth — a phenotype consistent with higher TBX21 promoter activity in this group. Higher TBX21-driven T-bet expression might seem paradoxically Th1-promoting, but the neonatal cytokine secretion pattern suggests a more complex regulatory picture: in the cord blood context, the T allele may increase an early Th2-priming innate response that sets up atopic sensitization. The same T allele has been observed at higher frequency in Graves' disease patients who fail to achieve remission (Morita 2012) and in SLE patients (You et al. 2010), indicating the T allele broadly promotes cytokine-driven immune activity that can manifest as atopy (Th2 excess) or autoimmunity (Th1 excess) depending on genetic background and environmental context.